Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2007 1
2008 2
2009 1
2010 2
2013 1
2014 2
2016 4
2017 5
2018 6
2019 3
2020 8
2021 4
2022 1
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Primary Sclerosing Cholangitis: Gender Effects in Valencia's Low-Prevalence Region.
Mínguez A, Conde I, Montón C, Gonzalez L, Pascual S, Antón MD, Palau A, Forés A, Gisbert C, Ojeda A, Girona E, Di Maira T, Berenguer M. Mínguez A, et al. Among authors: conde i. Dig Dis Sci. 2024 Mar 22. doi: 10.1007/s10620-024-08368-y. Online ahead of print. Dig Dis Sci. 2024. PMID: 38517562
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries.
Medina-Cáliz I, Sanabria-Cabrera J, Villanueva-Paz M, Aukštikalnė L, Stephens C, Robles-Díaz M, Pinazo-Bandera JM, García-Cortes M, Conde I, Soriano G, Bessone F, Hernandez N, Nunes V, Paraná R, Lucena MI, Andrade RJ, Niu H, Alvarez-Alvarez I. Medina-Cáliz I, et al. Among authors: conde i. Arch Toxicol. 2024 Jan;98(1):303-325. doi: 10.1007/s00204-023-03630-0. Epub 2023 Dec 5. Arch Toxicol. 2024. PMID: 38051367 Free PMC article.
Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries.
García-Cortés M, Ortega-Alonso A, Matilla-Cabello G, Medina-Cáliz I, Castiella A, Conde I, Bonilla-Toyos E, Pinazo-Bandera J, Hernández N, Tagle M, Nunes V, Parana R, Bessone F, Kaplowitz N, Lucena MI, Alvarez-Alvarez I, Robles-Díaz M, Andrade RJ. García-Cortés M, et al. Among authors: conde i. Liver Int. 2023 Aug;43(8):1749-1760. doi: 10.1111/liv.15623. Epub 2023 Jun 3. Liver Int. 2023. PMID: 37269163
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
Díaz-González Á, Hernández-Guerra M, Pérez-Medrano I, Sapena V, Riveiro-Barciela M, Barreira-Díaz A, Gómez E, Morillas RM, Del Barrio M, Escudé L, Mateos B, Horta D, Gómez J, Conde I, Ferre-Aracil C, El Hajra I, Arencibía A, Zamora J, Fernández A, Salcedo M, Molina E, Soria A, Estévez P, López C, Álvarez-Navascúes C, García-Retortillo M, Crespo J, Londoño MC; ColHai Registry. Díaz-González Á, et al. Among authors: conde i. Hepatology. 2023 Apr 1;77(4):1095-1105. doi: 10.1097/HEP.0000000000000018. Epub 2023 Jan 3. Hepatology. 2023. PMID: 36626622 Free article.
Ertapenem neurotoxicity in liver transplantation.
Martínez Delgado S, Mínguez Sabater A, Ladrón Abia P, Aguilera Sancho-Tello MV, García Eliz M, Conde I. Martínez Delgado S, et al. Among authors: conde i. Rev Esp Enferm Dig. 2022 Apr;114(4):240-241. doi: 10.17235/reed.2021.8469/2021. Rev Esp Enferm Dig. 2022. PMID: 34933565 Free article.
Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes.
Ampuero J, Lucena A, Hernández-Guerra M, Moreno-Moraleda I, Arenas J, Conde I, Muñoz L, Canillas L, Fernandez E, Quiñones R, Simon MA, Gómez-Dominguez E, Gutierrez ML, Fernandez-Rodriguez C, Domper-Arnal MJ, Jorquera F, Garcia-Buey ML, Garcia-Retortillo M, Morillas R, Berenguer M, Casado M, Morales-Arraez D, Sousa JM, Molina E. Ampuero J, et al. Among authors: conde i. Gut. 2021 Dec 7:gutjnl-2021-325700. doi: 10.1136/gutjnl-2021-325700. Online ahead of print. Gut. 2021. PMID: 34876479 No abstract available.
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
Stephens C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, Ortega-Alonso A, Sanabria-Cabrera J, Gonzalez-Jimenez A, Alvarez-Alvarez I, Slim M, Jimenez-Perez M, Gonzalez-Grande R, Fernández MC, Casado M, Soriano G, Román E, Hallal H, Romero-Gomez M, Castiella A, Conde I, Prieto M, Moreno-Planas JM, Giraldez A, Moreno-Sanfiel JM, Kaplowitz N, Lucena MI, Andrade RJ; Participating clinical centres. Stephens C, et al. Among authors: conde i. J Hepatol. 2021 Jul;75(1):86-97. doi: 10.1016/j.jhep.2021.01.029. Epub 2021 Feb 1. J Hepatol. 2021. PMID: 33539847 Free article.
Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
Gomez E, Garcia Buey L, Molina E, Casado M, Conde I, Berenguer M, Jorquera F, Simón MA, Olveira A, Hernández-Guerra M, Mesquita M, Presa J, Costa-Moreira P, Macedo G, Arenas JI, Manuel Sousa J, Ampuero J, Morillas RM, Santos A, De Carvalho A, Uriz J, Carrión JA, Luisa Gutiérrez M, Pérez-Fernández E, Fernández-Rodríguez CM; IBER-PBC leading Cooperative Group. Gomez E, et al. Among authors: conde i. Aliment Pharmacol Ther. 2021 Feb;53(4):519-530. doi: 10.1111/apt.16181. Epub 2020 Dec 12. Aliment Pharmacol Ther. 2021. PMID: 33314220
42 results